CLINICAL TRIALS COMPARING IMMUNOTHERAPY PLUS STEREOTACTIC ABLATIVE RADIOTHERAPY (I-SABR) VERSUS SABR ALONE FOR STAGE I, SELECTED STAGE IIA OR ISOLATED LUNG PARENCHYMAL RECURRENT NON-SMALL CELL LUNG CANCER: I-SABR: